Home › Insights › Sector comparison
Pharmaceutical Stocks in Pakistan: Price, Performance and Trend Compared
Updated 2026-11-18 · by FoxLogica
FoxLogica's data covers 15 PSX-listed pharmaceutical companies with current prices. Over about six months their average price change is -8.3%, and over about a month -0.5%, with 10 of 15 higher over the month. The widest gap is between Otsuka Pakistan Limited (OTSU, +65.9% over six months) and Macter International Limited (MACTER, -81.6%).
Pharmaceutical stocks compared
| Company | Last close (PKR) | 1M | 3M | 6M | 52-week closing range (PKR) | Short-term trend |
|---|---|---|---|---|---|---|
| AGP Limited (AGP) | 153.52 | -7.0% | -15.3% | -13.9% | 147.29 – 243.29 | neutral (sideways) |
| Abbott Laboratories (Pakistan) Limited (ABOT) | 1,005.51 | +6.1% | +11.7% | +15.6% | 836.92 – 1,257.76 | neutral (sideways) |
| BF Biosciences Limited (BFBIO) | 135.27 | +7.3% | -2.1% | +1.9% | 119.97 – 172.23 | neutral (sideways) |
| Citi Pharma Ltd. (CPHL) | 62.36 | +0.0% | -13.4% | -20.1% | 58.22 – 92.24 | neutral (sideways) |
| Crestwell Healthcare Limited (CWHC) | 20.56 | -12.8% | -67.6% | -72.8% | 12.63 – 120.48 | neutral (sideways) |
| Ferozsons Laboratories Limited (FEROZ) | 354.42 | +6.0% | -2.7% | -4.0% | 299.96 – 454.59 | neutral (sideways) |
| GlaxoSmithKline Pakistan Limited (GLAXO) | 333.13 | +6.1% | -2.1% | -4.0% | 293.09 – 450.61 | neutral (sideways) |
| Haleon Pakistan Limited (HALEON) | 682.26 | +0.7% | -6.0% | -10.2% | 650.73 – 989.01 | neutral (sideways) |
| Highnoon Laboratories Limited (HINOON) | 964.66 | +2.8% | -1.9% | +1.6% | 755.56 – 1,131.98 | neutral (sideways) |
| Hoechst Pakistan Limited (HPL) | 4,000.86 | -0.8% | +0.0% | +0.1% | 3,799.87 – 4,808.99 | neutral (sideways) |
| IBL HealthCare Limited (IBLHL) | 40.93 | -0.3% | -16.0% | -10.1% | 37.33 – 80.28 | neutral (sideways) |
| Liven Pharma Limited (LIVEN) | 43.31 | +37.6% | +24.2% | +16.9% | 28.85 – 67.10 | neutral (sideways) |
| Macter International Limited (MACTER) | 50.07 | -79.4% | -81.9% | -81.6% | 50.07 – 359.31 | neutral (sideways) |
| Otsuka Pakistan Limited (OTSU) | 465.89 | +22.9% | +13.3% | +65.9% | 278.04 – 471.42 | neutral (sideways) |
| Searle Company Limited (SEARL) | 79.18 | +3.7% | -10.6% | -9.7% | 73.51 – 135.07 | neutral (sideways) |
Changes use daily closes over about 21, 63 and 126 trading sessions. The trend column is the short-term reading from FoxLogica's analyzer. Companies with less than 60 sessions of data or stale prices are left out. Each company name links to its own technical analysis page.
What drives pharmaceutical stocks
- Drug pricing rules: medicine prices are regulated by DRAP, so approved price increases matter for margins.
- Imported raw materials: active ingredients are largely imported and paid for in foreign currency, so the PKR exchange rate affects costs.
- Demand and product mix: chronic-care and branded products tend to be steadier than one-off or tender-based sales.
- Regulation and supply: licensing, import approvals and availability of ingredients can affect production.
These are general sector drivers. Check each company's financial statements and announcements for company-specific factors.
Related pages
Frequently asked questions
Which pharmaceutical stocks are listed on the PSX?
FoxLogica's data covers 15 pharmaceutical companies with current prices. They are listed in the table above with links to their technical analysis pages.
How have pharmaceutical stocks performed recently?
On average about -0.5% over roughly a month and -8.3% over roughly six months, based on daily closes in FoxLogica's data as of the update date.
Which pharmaceutical stock is best?
FoxLogica does not recommend stocks. Compare performance, financial statements, debt and dividends before deciding, and consider a licensed adviser.
Is this page investment advice?
No. It is educational and shows data only.
Disclaimer: Trading in stocks and securities involves substantial risk of loss. FoxLogica provides educational content, analytical tools and community insights, not personalized licensed financial advice, and is not a registered brokerage or advisory firm unless separately stated. Nothing here is a recommendation to buy, hold or sell, or a forecast. Past performance is not indicative of future results.